Sign in
IAM Stock Price, Chart, Stats & News
Iambic Therapeutics Inc.
Save
Iambic Therapeutics Inc. (IAM) does not currently pay a dividend.
223.22M
Market cap
–
Current P/E
–
Forward P/E
IAM chart
Price history is unavailable
We don't have enough price data for IAM to draw a chart yet.
Fundamentals
Gross margin | 86.87% |
Operating margin | 38.27% |
Pretax margin | 35.04% |
Net margin | 19.37% |
Effective tax rate | 38.17% |
ROA | 10.04% |
ROE | 43.54% |
D/E | 1.39x |
Interest coverage ratio | 8.75x |
IAM valuation
P/E | – |
P/S | 2.63x |
P/B | 5.48x |
P/CF | 6.36x |
P/FCF | 29.10x |
P/OCF | 6.36x |
PEG | 0.05x |
EV multiple | 7.76x |
About
Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.
Similar securities
Based on sector and market capitalization
Report issue